



Content highlights

Release date

December 2024

Updated throughout the year to reflect Clarivate's expert analysis of the latest major-market events

Geography

United States, EU5, Japan

Primary research

20 country-specific interviews with thought-leading cardiologists

Supported by survey data collected for this and other Clarivate research

Epidemiology

Diagnosed events of AHF by country and diagnosed prevalence of CHF by country, segmented by ejection fraction

Forecast

10-year, annualized, drug-level sales and patient share of key heart failure therapies through 2033, segmented by brands / generics, country and ejection fraction

Drug treatments

Coverage of key current and emerging therapies

Heart Failure

Spotlight on Disease Landscape & Forecast

Market outlook

Acute and chronic heart failure (HF) have distinct treatment pathways, and both are covered in this report. Although much progress has been made in the pharmacological management of HF, this progress relates mainly to chronic HF (CHF), particularly HF with reduced ejection fraction (HFrEF). SGLT-2 inhibitors have made a breakthrough into the treatment of HFrEF as well as HF with preserved ejection fraction (HFpEF) and are set to become the standard of care for HF regardless of ejection fraction. However, substantial unmet need remains in the treatment of HFpEF. This report provides insight into the current and future CHF and acute HF (AHF) markets, as well as the expected dynamics of the HFrEF and HFpEF markets following the entries of new therapies such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide.

Questions answered

- How large are the treatable AHF, HFrEF, and HFpEF populations, and how will diagnosis rates change over time?
- What are the drivers and constraints in the heart failure therapy market, and how will the market evolve through 2033?
- What are the greatest unmet needs in the treatment of heart failure? Which drugs in development will fulfill these unmet needs?
- How will the treatment of HFpEF evolve following the launches of semaglutide and tirzepatide for this population?
- Which emerging therapies generate the most enthusiasm among thought leaders, and what is the expected level of market penetration of these agents?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Learn more about Clarivate's full suite of heart failure solutions:

healthcare.support@clarivate.com | clarivate.com